文献速递肿瘤 PET/CT核素与放射性配体治疗

根治性前列腺切除术后生化复发患者基于PSMA PET/CT引导的挽救性放疗结局:一项双中心回顾性分析

Outcome after PSMA PET/CT based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a bi-institutional retrospective analysis.
PubMed 文献 · J Nucl Med · 2018-07-12

该双中心回顾性分析纳入90例根治性前列腺切除术后生化复发并接受PSMA PET/CT引导挽救性放疗的患者,PET阳性42/90(47%),中位随访23个月,无生化复发生存率为78%,PET阳性与阴性患者间无显著差异,PET阳性者74% vs PET阴性者82%(p>0.05),3级晚期泌尿生殖毒性2例,无≥3级胃肠道毒性。

要点

  • PET阳性者42/90(47%),其中仅瘤床复发24/42(27%)、仅盆腔淋巴结12/42(13%)、瘤床和盆腔淋巴结6/42(7%)。
  • 中位随访23个月,无生化复发生存率为78%。
  • PET阳性者无生化复发生存率74% vs PET阴性者82%(p>0.05),无显著差异。

核心结论

  • PSMA PET/CT引导的挽救性放疗是有效且安全的局部治疗选择。
  • PET阳性与PET阴性患者间无生化复发生存率无差异,提示对PET阳性病灶进行了有效靶向。
  • 作者认为,PSMA PET/CT在可及的情况下应提供给PSA复发患者以个体化治疗。

研究设计与样本

  • 双中心回顾性分析,共204例连续患者被转诊接受根治性前列腺切除术后挽救性放疗。
  • 排除PSA持续存在者109例和远处转移证据者5例,最终分析纳入90例生化复发并接受PSMA PET/CT引导挽救性放疗的患者。
  • PET阳性者于放疗开始前启动抗雄激素治疗;研究终点为无生化复发生存(PSA ≤ 0.2 ng/ml)。

主要发现

  • PET阳性病灶42/90(47%):仅瘤床复发24/42(27%),仅盆腔淋巴结12/42(13%),瘤床和盆腔淋巴结复发6/42(7%)。
  • 放疗前中位PSA为0.44(0.11 - 6.24)。
  • 累积总剂量:局部宏观肿瘤70.0 Gy(67.2 - 72 Gy),前列腺瘤床66 Gy(59.4 - 70.2 Gy),PET阳性淋巴结60.8 Gy(54 - 66 Gy),淋巴引流路径50.4 Gy(45 - 50.4 Gy)。
  • 中位随访23个月,无生化复发生存率为78%;末次随访时4例仍在接受抗雄激素治疗。
  • PET阳性者无生化复发生存率74% vs PET阴性者82%(p>0.05),无显著差异。

关键数值与推荐

  • 无生化复发生存定义为PSA ≤ 0.2 ng/ml。
  • 毒性分级采用NCI-CTCAE v4.03。

临床怎么用

  • 作者认为,PSMA PET/CT在可及的情况下应提供给PSA复发患者以个体化治疗。
  • 作者结论指出,PSMA PET/CT引导的挽救性放疗是有效且安全的局部治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) detects prostate cancer recurrence at low PSA levels. Radiotherapy with dose escalation to the former prostate bed has been associated with improved biochemical recurrence-free survival (BRFS). Thus, we hypothesized that PSMA PET/CT-guided salvage radiotherapy leads to improved BRFS. Methods: A total of 204 consecutive patients were referred for salvage radiotherapy following radical prostatectomy. PSMA PET/CT scans were performed and patients with PSA persistence (109 patients) or evidence of distant metastases (5 patients) were excluded from this analysis. Thus, the following analysis is based on a total of 90 patients who underwent PSMA PET/CT prior to radiotherapy due to biochemical recurrence and received salvage radiotherapy. In case of PET-positive findings, antiandrogen therapy was commenced before initiation of radiotherapy. BRFS (PSA ≤ 0.2 ng/ml) was defined as the study endpoint. Results: PET-positive lesions were detected in 42/90 (47%) patients: 24/42 (27%) fossa recurrence only, 12/42 (13%) pelvic lymph nodes only and 6/42 (7%) fossa and pelvic lymph node recurrence. Median PSA before radiotherapy was 0.44 (0.11 - 6.24). Cumulatively, a total dose of 70.0 Gy (67.2 - 72 Gy) was delivered to local macroscopic tumor, 66 Gy (59.4 - 70.2 Gy) to the prostatic fossa, 60.8 Gy (54 - 66 Gy) to PET-positive lymph nodes and 50.4 Gy (45 - 50.4 Gy) to the lymphatic pathways. After a median follow-up of 23 months, BRFS was 78%. Antiandrogen therapy was ongoing in 4 patients at last follow-up. No significant difference in BRFS between PET-positive (74%) vs. PET-negative patients (82%; p>0.05) was observed at last follow-up. Two patients had late genitourinary toxicity grade 3 and no patient had gastrointestinal toxicity ≥ 3 (NCI-CTCAE v4.03). Conclusion: PSMA PET/CT-guided salvage radiotherapy is an effective and safe local treatment option. No difference in BRFS between PET-positive and PET-negative patients was observed, indicating effective targeting of PET-positive lesions. PSMA PET/CT when readily available should be offered to patients with PSA recurrence for treatment individualization.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Schmidt-Hegemann NS, Stief C, Kim TH, et al. Outcome after PSMA PET/CT based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a bi-institutional retrospective analysis. J Nucl Med. 2018. PMID: 30002108. doi:10.2967/jnumed.118.212563

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。